Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
Xeris Biopharma Holdings Inc (NASDAQ: XERS) closed the day trading at $1.78 up 2.30% from the previous closing price of $1.74. In other words, the price has increased by $2.30 from its previous closing price. On the day, 1.32 million shares were traded. XERS stock price reached its highest trading level at $1.84 during the session, while it also had its lowest trading level at $1.695.
Ratios:
For a better understanding of XERS, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.23 and its Current Ratio is at 1.64.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Oppenheimer on March 28, 2024, initiated with a Outperform rating and assigned the stock a target price of $5.
On August 28, 2023, Craig Hallum started tracking the stock assigning a Buy rating and target price of $4.50.
On October 21, 2022, Jefferies started tracking the stock assigning a Buy rating and target price of $4.Jefferies initiated its Buy rating on October 21, 2022, with a $4 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 14 ’24 when Schmid John P. bought 4,500 shares for $2.16 per share. The transaction valued at 9,720 led to the insider holds 11,000 shares of the business.
SHERMAN JEFFREY W bought 5,400 shares of XERS for $10,098 on Nov 27 ’23. The Director now owns 5,400 shares after completing the transaction at $1.87 per share. On Nov 20 ’23, another insider, Pieper Steven, who serves as the insider of the company, bought 28,000 shares for $1.95 each. As a result, the insider paid 54,600 and bolstered with 1,176,912 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, XERS now has a Market Capitalization of 250006320 and an Enterprise Value of 406747168. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.53. Its current Enterprise Value per Revenue stands at 2.481 whereas that against EBITDA is -12.839.
Stock Price History:
The Beta on a monthly basis for XERS is 1.66, which has changed by -0.19457012 over the last 52 weeks, in comparison to a change of 0.23061275 over the same period for the S&P500. Over the past 52 weeks, XERS has reached a high of $3.26, while it has fallen to a 52-week low of $1.46. The 50-Day Moving Average of the stock is -26.79%, while the 200-Day Moving Average is calculated to be -19.56%.
Shares Statistics:
Over the past 3-months, XERS traded about 1.90M shares per day on average, while over the past 10 days, XERS traded about 1558370 shares per day. A total of 138.13M shares are outstanding, with a floating share count of 125.56M. Insiders hold about 10.60% of the company’s shares, while institutions hold 41.01% stake in the company. Shares short for XERS as of 1711584000 were 8984970 with a Short Ratio of 4.72, compared to 1709164800 on 9643267. Therefore, it implies a Short% of Shares Outstanding of 8984970 and a Short% of Float of 6.54.
Earnings Estimates
Investors are keenly observing as 6 analysts analyze and rate the current performance of Xeris Biopharma Holdings Inc (XERS) in the stock market.On average, analysts expect EPS of $-0.12 for the current quarter, with a high estimate of $-0.11 and a low estimate of $-0.14, while EPS last year was $-0.12. The consensus estimate for the next quarter is $-0.1, with high estimates of $-0.09 and low estimates of $-0.12.
Analysts are recommending an EPS of between $-0.29 and $-0.47 for the fiscal current year, implying an average EPS of $-0.38. EPS for the following year is $-0.22, with 5 analysts recommending between $-0.13 and $-0.35.
Revenue Estimates
6 analysts predict $41.81M in revenue for the current quarter. It ranges from a high estimate of $44M to a low estimate of $37.97M. As of the current estimate, Xeris Biopharma Holdings Inc’s year-ago sales were $33.2M, an estimated increase of 25.90% from the year-ago figure. For the next quarter, 6 analysts are estimating revenue of $45.1M, an increase of 18.70% less than the figure of $25.90% in the same quarter last year. There is a high estimate of $47.6M for the next quarter, whereas the lowest estimate is $43.88M.
A total of 6 analysts have provided revenue estimates for XERS’s current fiscal year. The highest revenue estimate was $194.2M, while the lowest revenue estimate was $176.7M, resulting in an average revenue estimate of $184.43M. In the same quarter a year ago, actual revenue was $163.91M, up 12.50% from the average estimate. Based on 6 analysts’ estimates, the company’s revenue will be $219.33M in the next fiscal year. The high estimate is $230.4M and the low estimate is $195.2M. The average revenue growth estimate for next year is up 18.90% from the average revenue estimate for this year.
